Subscribe To
BIOC / Biocept, Inc. says coronavirus testing drove strong rise in full-year 2021 revenue
BIOC News
By Seeking Alpha
August 30, 2023
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
Biocept, Inc. (NASDAQ:BIOC ) Business Update Conference Call August 30, 2023 4:00 PM ET Company Participants Jody Cain - LHA Antonino Morales - Presid more_horizontal
By InvestorPlace
August 25, 2023
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product. more_horizontal
By Proactive Investors
August 14, 2023
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology more_horizontal
By Proactive Investors
June 21, 2023
Biocept appoints Antonino Morales as president and chief executive officer
Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Mora more_horizontal
By InvestorPlace
May 25, 2023
Why Is Biocept (BIOC) Stock Down 42% Today?
Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering more_horizontal
By Proactive Investors
May 17, 2023
Biocept shares to commence trading on split-adjusted basis
Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock w more_horizontal
By Proactive Investors
April 17, 2023
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay more_horizontal
By Proactive Investors
March 24, 2023
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metas more_horizontal